ATXS
Price
$7.50
Change
-$0.25 (-3.23%)
Updated
Jan 17 closing price
Capitalization
423.26M
47 days until earnings call
ZVRA
Price
$8.05
Change
+$0.12 (+1.51%)
Updated
Jan 17 closing price
Capitalization
429.68M
41 days until earnings call
Ad is loading...

ATXS vs ZVRA

Header iconATXS vs ZVRA Comparison
Open Charts ATXS vs ZVRABanner chart's image
Astria Therapeutics
Price$7.50
Change-$0.25 (-3.23%)
Volume$237.44K
Capitalization423.26M
Zevra Therapeutics
Price$8.05
Change+$0.12 (+1.51%)
Volume$216.67K
Capitalization429.68M
ATXS vs ZVRA Comparison Chart
Loading...
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZVRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATXS vs. ZVRA commentary
Jan 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATXS is a Hold and ZVRA is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 19, 2025
Stock price -- (ATXS: $7.50 vs. ZVRA: $8.05)
Brand notoriety: ATXS and ZVRA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATXS: 68% vs. ZVRA: 40%
Market capitalization -- ATXS: $423.26M vs. ZVRA: $429.68M
ATXS [@Biotechnology] is valued at $423.26M. ZVRA’s [@Biotechnology] market capitalization is $429.68M. The market cap for tickers in the [@Biotechnology] industry ranges from $368.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATXS’s FA Score shows that 0 FA rating(s) are green whileZVRA’s FA Score has 1 green FA rating(s).

  • ATXS’s FA Score: 0 green, 5 red.
  • ZVRA’s FA Score: 1 green, 4 red.
According to our system of comparison, ZVRA is a better buy in the long-term than ATXS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATXS’s TA Score shows that 3 TA indicator(s) are bullish while ZVRA’s TA Score has 3 bullish TA indicator(s).

  • ATXS’s TA Score: 3 bullish, 2 bearish.
  • ZVRA’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, ATXS is a better buy in the short-term than ZVRA.

Price Growth

ATXS (@Biotechnology) experienced а +0.67% price change this week, while ZVRA (@Biotechnology) price change was -0.74% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.44%. For the same industry, the average monthly price growth was +2.65%, and the average quarterly price growth was -1.89%.

Reported Earning Dates

ATXS is expected to report earnings on May 08, 2025.

ZVRA is expected to report earnings on May 20, 2025.

Industries' Descriptions

@Biotechnology (-1.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ZVRA($430M) and ATXS($423M) have the same market capitalization . ZVRA YTD gains are higher at: -3.477 vs. ATXS (-16.107). ZVRA has higher annual earnings (EBITDA): -78.22M vs. ATXS (-100.97M). ATXS has more cash in the bank: 344M vs. ZVRA (89.4M). ATXS has less debt than ZVRA: ATXS (5.64M) vs ZVRA (59.9M). ZVRA has higher revenues than ATXS: ZVRA (24.5M) vs ATXS (0).
ATXSZVRAATXS / ZVRA
Capitalization423M430M98%
EBITDA-100.97M-78.22M129%
Gain YTD-16.107-3.477463%
P/E RatioN/AN/A-
Revenue024.5M-
Total Cash344M89.4M385%
Total Debt5.64M59.9M9%
FUNDAMENTALS RATINGS
ATXS vs ZVRA: Fundamental Ratings
ATXS
ZVRA
OUTLOOK RATING
1..100
6753
VALUATION
overvalued / fair valued / undervalued
1..100
62
Fair valued
82
Overvalued
PROFIT vs RISK RATING
1..100
10075
SMR RATING
1..100
9799
PRICE GROWTH RATING
1..100
6547
P/E GROWTH RATING
1..100
10029
SEASONALITY SCORE
1..100
85n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ATXS's Valuation (62) in the Biotechnology industry is in the same range as ZVRA (82) in the null industry. This means that ATXS’s stock grew similarly to ZVRA’s over the last 12 months.

ZVRA's Profit vs Risk Rating (75) in the null industry is in the same range as ATXS (100) in the Biotechnology industry. This means that ZVRA’s stock grew similarly to ATXS’s over the last 12 months.

ATXS's SMR Rating (97) in the Biotechnology industry is in the same range as ZVRA (99) in the null industry. This means that ATXS’s stock grew similarly to ZVRA’s over the last 12 months.

ZVRA's Price Growth Rating (47) in the null industry is in the same range as ATXS (65) in the Biotechnology industry. This means that ZVRA’s stock grew similarly to ATXS’s over the last 12 months.

ZVRA's P/E Growth Rating (29) in the null industry is significantly better than the same rating for ATXS (100) in the Biotechnology industry. This means that ZVRA’s stock grew significantly faster than ATXS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATXSZVRA
RSI
ODDS (%)
Bullish Trend 5 days ago
87%
N/A
Stochastic
ODDS (%)
N/A
Bullish Trend 5 days ago
85%
Momentum
ODDS (%)
N/A
Bearish Trend 5 days ago
77%
MACD
ODDS (%)
N/A
N/A
TrendWeek
ODDS (%)
Bearish Trend 5 days ago
86%
Bearish Trend 5 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 5 days ago
87%
Bearish Trend 5 days ago
78%
Advances
ODDS (%)
Bullish Trend 17 days ago
84%
Bullish Trend 17 days ago
82%
Declines
ODDS (%)
Bearish Trend 9 days ago
89%
Bearish Trend 5 days ago
79%
BollingerBands
ODDS (%)
Bullish Trend 5 days ago
82%
Bullish Trend 5 days ago
85%
Aroon
ODDS (%)
Bearish Trend 5 days ago
84%
Bearish Trend 5 days ago
83%
View a ticker or compare two or three
Ad is loading...
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZVRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
BTC.X104462.0400004705.133000
+4.72%
Bitcoin cryptocurrency
TSLA426.5012.68
+3.06%
Tesla
SPY597.585.94
+1.00%
SPDR® S&P 500® ETF Trust
AAPL229.981.72
+0.75%
Apple
GME27.51-0.21
-0.76%
GameStop Corp

ATXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATXS has been loosely correlated with KALV. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ATXS jumps, then KALV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATXS
1D Price
Change %
ATXS100%
-3.23%
KALV - ATXS
44%
Loosely correlated
+0.61%
KYMR - ATXS
44%
Loosely correlated
+0.79%
IMNM - ATXS
43%
Loosely correlated
+1.32%
CRNX - ATXS
42%
Loosely correlated
+2.38%
ORIC - ATXS
42%
Loosely correlated
-4.58%
More

ZVRA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZVRA has been loosely correlated with CRNX. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if ZVRA jumps, then CRNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZVRA
1D Price
Change %
ZVRA100%
+1.51%
CRNX - ZVRA
34%
Loosely correlated
+2.38%
RIGL - ZVRA
34%
Loosely correlated
+16.02%
KYMR - ZVRA
34%
Loosely correlated
+0.79%
ATXS - ZVRA
33%
Loosely correlated
-3.23%
QURE - ZVRA
33%
Poorly correlated
-1.13%
More